TecMed acquires Ypsomed’s diabetes care business: the advisors
Kellerhals Carrard advised Burgdorf-based TecMed as lead counsel on the company’s acquisition of Ypsomed’s diabetes care business for CHF 420 million, including earn-out. Moreover, Walder Wyss represented the selling part on throughout the transaction.
Closing is planned for the second half of 2025, while the new headquarters for 250 employees is already under construction in Burgdorf.
The context
Controlled by Willy Michel, TecMed provides intellectual property solutions for blood glucose measurement problems. With this particular acquisition, the company will add Ypsomed’s mylife Loop system to its own patch pump program.
The Kellerhals Carrard team
Managing partner Beat Brechbühl (pictured above) led the Kellerhals Carrard team on the matter, working alongside Marc Hanslin, Patric Brand, Roman Aus der Au, Danijel Gajic (all M&A), Jörg von Manger-Koenig (life sciences), Daniel Emch and Stefanie Karlen (antitrust), Eliane Haas (IP), Bettina Achermann (employment), Milena Grob (data protection), and Livio Marelli (real estate).
The Walder Wyss team
Corporate and M&A partners Hans-Jakob Diem (pictured left) and Dominik Hohler (pictured right) led the Walder Wyss team on the matter, working alongside senior associates Letizia Schlegel and Michael Kissling (both corporate/M&A), trainee Arbër Hyseni (corporate/M&A), partner Michael Isler (IP/data protection and regulatory) and associate Kento Reutimann (IP/data protection).
